Source/Disclosures
Source:

Hamza MME, et al. Retina. 2016;doi:10.1097/IAE.0000000000001109.

December 06, 2016
1 min read
Save

Improvements seen with intravitreal infliximab for treatment of uveitis in Behçet's disease

Source/Disclosures
Source:

Hamza MME, et al. Retina. 2016;doi:10.1097/IAE.0000000000001109.

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Intravitreal infliximab for the treatment of refractory posterior uveitis in Behçet’s disease significantly improved logMAR best corrected visual acuity and decreased central foveal thickness, according to a study.

Researchers included 20 patients with refractory posterior uveitis in Behçet’s disease and assessed BCVA, vitreous haze, vasculitis, papillopathy and retinitis at baseline and postoperatively at day 1 and weeks 2, 4, 6, 8, 12 and 18. Additionally, flash electroretinogram and OCT were examined at baseline and postoperatively at weeks 4, 12 and 18.

Patients were treated with three consecutive intravitreal injections of 1 mg of infliximab, 6 weeks apart, for 18 weeks.

Mean baseline BCVA improved significantly by week 2, continued to improve by week 4, did not change significantly between weeks 4, 6 and 8, worsened by week 12, and improved again by week 18.

Mean baseline central foveal thickness improved significantly by week 4 and continued to improve by week 18.
“Based on the results of our study and previous clinical studies, intravitreal infliximab appeared to be very effective in cases of posterior noninfectious uveitis including Behçet’s disease. The intravitreal infliximab dose of 1 mg was well tolerated with no observed adverse effects clinically and by flash ERG. However, these effects were temporary and reinjections were needed perhaps at intervals shorter than 6 weeks,” the researchers wrote.

Disclosure: The authors report no relevant financial disclosures.